[go: up one dir, main page]

NO20005463L - Nye fettsyreanaloger for behandling av primær og sekundær restenose - Google Patents

Nye fettsyreanaloger for behandling av primær og sekundær restenose

Info

Publication number
NO20005463L
NO20005463L NO20005463A NO20005463A NO20005463L NO 20005463 L NO20005463 L NO 20005463L NO 20005463 A NO20005463 A NO 20005463A NO 20005463 A NO20005463 A NO 20005463A NO 20005463 L NO20005463 L NO 20005463L
Authority
NO
Norway
Prior art keywords
sub
treatment
fatty acid
primary
acid analogues
Prior art date
Application number
NO20005463A
Other languages
English (en)
Other versions
NO20005463D0 (no
Inventor
Rolf Berge
Original Assignee
Thia Medica As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thia Medica As filed Critical Thia Medica As
Priority to NO20005463A priority Critical patent/NO20005463L/no
Publication of NO20005463D0 publication Critical patent/NO20005463D0/no
Publication of NO20005463L publication Critical patent/NO20005463L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Fats And Perfumes (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Edible Oils And Fats (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO20005463A 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose NO20005463L (no)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NO20005463A NO20005463L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/NO1998/000143 WO1999058120A1 (en) 1998-05-08 1998-05-08 USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
PCT/NO1999/000149 WO1999058123A2 (en) 1998-05-08 1999-05-07 Novel fatty acid analogues for the treatment of primary and secondary restenosis
NO20005463A NO20005463L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose

Publications (2)

Publication Number Publication Date
NO20005463D0 NO20005463D0 (no) 2000-10-30
NO20005463L true NO20005463L (no) 2001-01-08

Family

ID=19907879

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20005463A NO20005463L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av primær og sekundær restenose
NO20005462A NO333143B1 (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av diabetes
NO20005461A NO20005461L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20005462A NO333143B1 (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av diabetes
NO20005461A NO20005461L (no) 1998-05-08 2000-10-30 Nye fettsyreanaloger for behandling av obesitet, hypertensjon og fettlever

Country Status (17)

Country Link
US (4) US6441036B1 (no)
EP (5) EP1284139B1 (no)
JP (3) JP5057003B2 (no)
KR (3) KR100701502B1 (no)
CN (3) CN1245157C (no)
AT (5) ATE245416T1 (no)
AU (4) AU7240398A (no)
BR (2) BR9910296A (no)
CA (3) CA2331395C (no)
DE (5) DE69932864D1 (no)
DK (3) DK1075258T3 (no)
ES (3) ES2204142T3 (no)
NO (3) NO20005463L (no)
NZ (3) NZ508047A (no)
PT (2) PT1075259E (no)
RU (3) RU2219920C2 (no)
WO (4) WO1999058120A1 (no)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275140A2 (en) 2004-07-19 2011-01-19 Thia Medica AS Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
AUPQ291499A0 (en) * 1999-09-17 1999-10-07 Women's And Children's Hospital Adelaide Novel nitro and sulphur containing compounds
AU784588B2 (en) * 1999-09-17 2006-05-04 Peplin Biolipids Pty Ltd Anti-inflammatory nitro- and thia- fatty acids
CA2704975A1 (en) * 1999-10-13 2001-05-31 Marco A. Chacon Therapeutic intervention to mimic the effect of caloric restriction
NO328803B1 (no) * 2000-03-03 2010-05-18 Thia Medica Nye fettsyreanaloger
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
NO20004844L (no) * 2000-09-27 2002-05-10 Thia Medica As Fettsyre analoger for behandling av proliferative hudsykdommer
NO20006008L (no) 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
DE10115740A1 (de) * 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
ES2186576B1 (es) * 2001-10-11 2004-09-16 Universitat De Les Illes Balears Acido 2-hidroxioleico para utilizar como medicamento.
US6908632B1 (en) 2002-04-19 2005-06-21 Pharmanex, Llc Blood glucose modulating compositions and methods
DE60335810D1 (de) * 2002-05-28 2011-03-03 Ajinomoto Kk Medizinische zusammensetzungen zur hemmung der expression von atp-citrat-lyase und ihre verwendung
CA2490121C (en) 2002-06-20 2013-01-08 Ic Vec Limited Modified phospholipids
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7045547B2 (en) * 2002-08-20 2006-05-16 University Of Delaware Acyl-CoA dehydrogenase allenic inhibitors
UA79309C2 (en) 2002-09-06 2007-06-11 Janssen Pharmaceutica Nv Heterocyclic compounds
EP2384750A1 (en) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
ZA200502613B (en) * 2002-10-10 2006-10-25 Yeda Res & Dev Basic esters of fatty alcohols and their use as anti-inflammatory or immunomodulatory agents
FR2850650B1 (fr) * 2003-01-31 2005-03-25 Genfit S A Utilisation therapeutique d'acylglycerols et de leurs analogues azotes et sulfures
FR2850869B1 (fr) * 2003-02-12 2005-03-25 Genfit S A Utilisations d'aminopropanediols acyles et de leurs analogues azotes et sulfures
EP1594439A2 (en) * 2003-02-13 2005-11-16 Albert Einstein College Of Medicine Of Yeshiva University REGULATION OF FOOD INTAKE AND GLUCOSE PRODUCTION BY MODULATION OF LONG-CHAIN FATTY ACYL-CoA LEVELS IN THE HYPOTHALAMUS
PL377614A1 (pl) * 2003-03-18 2006-02-06 Novartis Ag Kompozycje zawierające kwasy tłuszczowe i aminokwasy
AU2005209331A1 (en) * 2004-01-30 2005-08-11 Peplin Biolipids Pty Ltd Therapeutic and carrier molecules
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
CN1961213A (zh) * 2004-05-28 2007-05-09 詹森药业有限公司 新的在清醒大鼠中静脉给药和血液取样模型
DE102004034640A1 (de) 2004-07-16 2006-02-16 Institut für Molekular- und Systemmedizin Verfahren zur systemischen Biokorrektur eines Organismus
NO324534B1 (no) * 2004-07-19 2007-11-19 Thia Medica As Materiale fremstilt fra en kombinasjon av ikke-β-oksiderbare fettsyreanaloger og en planteolje eller fiskeolje samt anvendelser derav
RU2388490C2 (ru) * 2004-07-19 2010-05-10 Тиа Медика Ас Композиция, содержащая растительный или рыбий жир, и соединения, содержащие неокисляющиеся структурные элементы жирных кислот
RU2272628C1 (ru) * 2004-07-19 2006-03-27 Илья Николаевич Медведев Способ быстрой оптимизации функций кровяных пластинок при метаболическом синдроме
WO2006041922A2 (en) * 2004-10-08 2006-04-20 Dara Biosciences, Inc. Agents and methods for administration to the central nervous system
US7288525B2 (en) * 2004-12-28 2007-10-30 The Research Foundation Of State University Of New York Method for lowering serum homocysteine
US20090012067A1 (en) * 2005-02-14 2009-01-08 Luciano Rossetti Modulation of Hypothalamic Atp-Sensitive Potassium Channels
RU2441061C2 (ru) * 2005-05-04 2012-01-27 Пронова Биофарма Норге Эс. Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
JP2008540394A (ja) * 2005-05-04 2008-11-20 プロノヴァ バイオファーマ ノルゲ アクティーゼルスカブ 脂肪酸組成物、即ち、ｄｈａ誘導体の医薬としての使用
US7586003B2 (en) * 2005-07-14 2009-09-08 Zinpro Corporation Derivatives of seleno-amino acids
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
NO20055541L (no) * 2005-11-23 2007-05-24 Berge Biomed As Use of fatty acid analogues
GB0605900D0 (en) * 2006-03-23 2006-05-03 Lipigen As Modulators of nuclear receptors
US20080085293A1 (en) * 2006-08-22 2008-04-10 Jenchen Yang Drug eluting stent and therapeutic methods using c-Jun N-terminal kinase inhibitor
PT2724722T (pt) * 2006-10-20 2017-03-14 Neurendo Pharma Llc Método de restaurar o efeito incretina
KR101438177B1 (ko) * 2006-11-01 2014-09-05 프로노바 바이오파마 너지 에이에스 페록시솜 증식자-활성화 수용체의 활성자 또는 조절자인 알파-치환된 오메가-3 지질
US20100240616A1 (en) * 2006-11-01 2010-09-23 Anne Kristin Holmeide Novel lipid compounds
US7964751B2 (en) * 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
WO2008106091A1 (en) * 2007-02-26 2008-09-04 Yeda Research And Development Co. Ltd. Use of long-chain alcohol derivatives for the treatment of alopecia areata
ES2748136T3 (es) 2007-10-15 2020-03-13 United Animal Health Inc Método para aumentar el rendimiento de las crías
WO2009056983A1 (en) * 2007-10-31 2009-05-07 Pronova Biopharma Norge As New dha derivatives and their use as medicaments
US8986253B2 (en) 2008-01-25 2015-03-24 Tandem Diabetes Care, Inc. Two chamber pumps and related methods
WO2009132979A1 (en) * 2008-04-29 2009-11-05 F. Hoffmann-La Roche Ag 4-trimethylammonio-butyrates as cpt2 inhibitors
EP2147910A1 (en) * 2008-07-15 2010-01-27 Pronova BioPharma Norge AS Novel lipid compounds
US8408421B2 (en) 2008-09-16 2013-04-02 Tandem Diabetes Care, Inc. Flow regulating stopcocks and related methods
CA2737461A1 (en) 2008-09-19 2010-03-25 Tandem Diabetes Care, Inc. Solute concentration measurement device and related methods
PL2427415T3 (pl) 2009-05-08 2019-09-30 Basf As Wielonienasycone kwasy tłuszczowe do leczenia chorób związanych z dziedziną chorób sercowo-naczyniowych, metabolicznych i zapalnych
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
CA2921304C (en) 2009-07-30 2018-06-05 Tandem Diabetes Care, Inc. Infusion pump system with disposable cartridge having pressure venting and pressure feedback
US20120028335A1 (en) 2010-07-28 2012-02-02 Life Technologies Corporation Anti-viral azide-containing compounds
US9144575B2 (en) 2010-07-28 2015-09-29 Life Technologies Corporation Anti-viral azide containing compounds
NZ610705A (en) 2010-11-05 2014-10-31 Pronova Biopharma Norge As Methods of treatment using lipid compounds
US9180242B2 (en) 2012-05-17 2015-11-10 Tandem Diabetes Care, Inc. Methods and devices for multiple fluid transfer
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
KR102213143B1 (ko) 2013-02-28 2021-02-08 바스프 에이에스 지방질 화합물, 트리글리세리드 및 계면활성제를 포함하는 조성물 및 이를 이용하는 방법
AU2014228387B2 (en) 2013-03-11 2016-09-01 Sciadonics, Inc. Lipid compositions containing bioactive fatty acids
US9173998B2 (en) 2013-03-14 2015-11-03 Tandem Diabetes Care, Inc. System and method for detecting occlusions in an infusion pump
RU2522224C1 (ru) * 2013-08-06 2014-07-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная академия ветеринарной медицины" Способ лечения острого гепатоза у кошек
US10034871B2 (en) 2014-11-07 2018-07-31 Regents Of The University Of Minnesota Salts and compositions useful for treating disease
BR112017023164A2 (en) 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
US10492141B2 (en) 2015-11-17 2019-11-26 Tandem Diabetes Care, Inc. Methods for reduction of battery usage in ambulatory infusion pumps
EP3661600A4 (en) 2017-10-23 2021-08-11 Epitracker, Inc. FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
BR112020011431A2 (pt) 2017-12-06 2020-11-24 Basf As derivados de ácido graxo para o tratamento de esteato-hepatite não alcoólica
AU2019274431B2 (en) 2018-05-23 2025-03-13 Epitracker, Inc. Compositions and methods for diagnosis and treatment of conditions related to the quality of aging and longevity
EP3908374A4 (en) 2019-01-09 2022-12-28 Epitracker, Inc. COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF NEURODEGENERATIVE DISEASES
JP7404382B2 (ja) * 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
WO2023080939A1 (en) 2021-11-03 2023-05-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
KR20250043868A (ko) 2023-09-22 2025-03-31 건국대학교 산학협력단 옥시리핀을 유효성분으로 포함하는 비만 예방 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59175425A (ja) * 1983-03-25 1984-10-04 Otsuka Pharmaceut Co Ltd 脳卒中予防剤
GB8813012D0 (en) * 1988-06-02 1988-07-06 Norsk Hydro As Non-b-oxidizable fatty acid analogues to reduce concentration of cholesterol & triglycerides in blood of mammals
US6063581A (en) * 1992-01-22 2000-05-16 Axis-Shield Asa Immunoassay for homocysteine
CA2223595C (en) * 1995-06-07 2008-08-05 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
NO952796D0 (no) * 1995-07-14 1995-07-14 Rolf Berge Fettsyre analoger med ikkeoksyderbart B-sete, fremstilling og anvendelse i krapeutiske preparater
DE69622722T2 (de) * 1996-11-20 2003-02-27 N.V. Nutricia, Zoetermeer Fette enthaltende Ernährungszusammensetzung zur Behandlung des Stoffwechselsyndroms
AU7240398A (en) * 1998-05-08 1999-11-29 Rolf Berge Use of non-beta-oxidizable fatty acid analogues for treatment of syndrome-x conditions

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2275140A2 (en) 2004-07-19 2011-01-19 Thia Medica AS Composition comprising plant and/or fish oils and non-oxidizable fatty acid entities
WO2014140934A2 (en) 2013-03-11 2014-09-18 Life Science Nutrition As Natural lipids containing non-oxidizable fatty acids

Also Published As

Publication number Publication date
EP1285652B1 (en) 2006-08-16
WO1999058122A1 (en) 1999-11-18
CN1300211A (zh) 2001-06-20
DE69927805T2 (de) 2006-07-06
NO20005461D0 (no) 2000-10-30
PT1075258E (pt) 2004-01-30
EP1075258B1 (en) 2003-08-20
US6365628B1 (en) 2002-04-02
CA2331395C (en) 2008-10-14
EP1284139A1 (en) 2003-02-19
ATE245416T1 (de) 2003-08-15
KR100822077B1 (ko) 2008-04-14
CN1300212A (zh) 2001-06-20
AU5451799A (en) 1999-11-29
EP1075259A1 (en) 2001-02-14
KR20010043316A (ko) 2001-05-25
RU2219920C2 (ru) 2003-12-27
NO333143B1 (no) 2013-03-18
DE69909775D1 (de) 2003-08-28
DE69910559D1 (de) 2003-09-25
EP1075258A1 (en) 2001-02-14
ES2251218T3 (es) 2006-04-16
ATE334666T1 (de) 2006-08-15
NO20005463D0 (no) 2000-10-30
KR20010043315A (ko) 2001-05-25
BR9910296A (pt) 2002-01-15
DE69927805D1 (de) 2006-03-02
CA2331408A1 (en) 1999-11-18
HK1034909A1 (en) 2001-11-09
ATE336239T1 (de) 2006-09-15
US7026356B2 (en) 2006-04-11
CN1223343C (zh) 2005-10-19
AU762790B2 (en) 2003-07-03
CN1302204A (zh) 2001-07-04
RU2223095C2 (ru) 2004-02-10
DK1075259T3 (da) 2003-11-03
ES2207253T3 (es) 2004-05-16
CN1244323C (zh) 2006-03-08
AU4936699A (en) 1999-11-29
DK1075258T3 (da) 2003-12-01
ATE247464T1 (de) 2003-09-15
EP1285652A1 (en) 2003-02-26
KR20010043314A (ko) 2001-05-25
US6417232B1 (en) 2002-07-09
CN1245157C (zh) 2006-03-15
CA2331393C (en) 2009-08-11
NO20005462L (no) 2001-01-08
AU761355B2 (en) 2003-06-05
DK1075260T3 (da) 2006-02-06
DE69909775T2 (de) 2004-06-03
HK1034911A1 (en) 2001-11-09
PT1075259E (pt) 2003-12-31
US6441036B1 (en) 2002-08-27
RU2221558C2 (ru) 2004-01-20
US20020198259A1 (en) 2002-12-26
NO20005462D0 (no) 2000-10-30
CA2331408C (en) 2008-10-21
EP1075260A2 (en) 2001-02-14
KR100701502B1 (ko) 2007-04-02
JP2002514595A (ja) 2002-05-21
NZ508046A (en) 2003-08-29
AU7240398A (en) 1999-11-29
AU762792B2 (en) 2003-07-03
NZ508047A (en) 2003-05-30
JP5057003B2 (ja) 2012-10-24
JP2002514596A (ja) 2002-05-21
WO1999058121A1 (en) 1999-11-18
ATE306916T1 (de) 2005-11-15
JP2002514594A (ja) 2002-05-21
ES2204142T3 (es) 2004-04-16
CA2331395A1 (en) 1999-11-18
DE69932864D1 (de) 2006-09-28
WO1999058120A1 (en) 1999-11-18
EP1075260B1 (en) 2005-10-19
HK1034912A1 (en) 2001-11-09
NO20005461L (no) 2001-01-08
WO1999058123A2 (en) 1999-11-18
NZ508045A (en) 2003-08-29
JP4465672B2 (ja) 2010-05-19
DE69932645D1 (de) 2006-09-14
CA2331393A1 (en) 1999-11-18
DE69910559T2 (de) 2004-06-17
BR9910297A (pt) 2002-01-02
WO1999058123A3 (en) 2000-03-09
EP1075259B1 (en) 2003-07-23
AU4936799A (en) 1999-11-29
KR100701503B1 (ko) 2007-04-02
EP1284139B1 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
NO20005463D0 (no) Nye fettsyreanaloger for behandling av primær og sekundær restenose
AU2019502A (en) Anilinopyrimidine derivatives as ikk inhibitors and compositions and methods related thereto
AU2721402A (en) Anilinopyrimidine derivatives as jnk pathway inhibitors and compositions and methods related thereto
DK1485359T3 (da) Natriumkanalblokkere
DE69928697D1 (de) Sulfohydroxamsäure and sulfohydroxamate und ihre verwendung als mek-inhibitoren
WO2004018431A3 (en) Novel phenanthridines
AP2002002637A0 (en) Novel piperazine
ATE224385T1 (de) Kristallmodifikation der liponsäure
TR200201128T2 (tr) PDE4 inhibitörleri olarak tetrahidrotiyopiranfitalazinon türevleri.
BR0212899A (pt) Compostos orgânicos
DK1204659T3 (da) Serotonerge benzofuraner
ZA200500436B (en) 6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
TR199903159T2 (xx) Yeni �-Amino ve �-Azido karbonik asit t�revleri.
SI1651596T1 (sl) Novi derivati ditiobis aminobutan sulfonatov in sestavki ki jih vsebujejo
DE69405760D1 (de) 4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
EP1195377A4 (en) DIESTERS OF MALEIC OR FUMARIC ACID
PT1294729E (pt) 2-aminoalquil-tieno[2,3-d]pirimidinas
WO2004020417A8 (en) 2,4-diaminoquinazoline, 2-amino-4-hydroxypteridine and 2,4-diaminopyrimidine ester derivatives as dihydrofolate reductase inhibitors
BR0316971A (pt) Fenilalquinas
MX9708155A (es) Inhibicion de la fotodescomposicion de 2-oxindoles 3-sustituidos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application